NCT03349957View on ClinicalTrials.gov

TACE for HCC by TANDEM and Idarubicin

CompletedOBSERVATIONAL
Enrollment

98

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

January 30, 2018

Study Completion Date

March 30, 2018

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Transarterial chemoembolization using TANDEM and idarubicin

Transarterial chemoembolization using TANDEM and idarubicin

Trial Locations (1)

34295

Uhmontpellier, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT03349957 - TACE for HCC by TANDEM and Idarubicin | Biotech Hunter | Biotech Hunter